Micropapillary bladder cancer A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients

Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience. The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated a...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 110; no. 1; pp. 62 - 67
Main Authors Kamat, Ashish M., Dinney, Colin P. N., Gee, Jason R., Grossman, H. Barton, Siefker‐Radtke, Arlene O., Tamboli, Pheroze, Detry, Michelle A., Robinson, Tracy L., Pisters, Louis L.
Format Journal Article
LanguageEnglish
Published New York, NY Wiley-Liss 01.07.2007
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience. The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center. The mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years. Micropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.
AbstractList Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience. The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center. The mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years. Micropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.
Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.BACKGROUNDMicropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center.METHODSThe authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center.The mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.RESULTSThe mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.Micropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.CONCLUSIONSMicropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.
Author Detry, Michelle A.
Kamat, Ashish M.
Grossman, H. Barton
Siefker‐Radtke, Arlene O.
Pisters, Louis L.
Tamboli, Pheroze
Robinson, Tracy L.
Gee, Jason R.
Dinney, Colin P. N.
Author_xml – sequence: 1
  givenname: Ashish M.
  surname: Kamat
  fullname: Kamat, Ashish M.
– sequence: 2
  givenname: Colin P. N.
  surname: Dinney
  fullname: Dinney, Colin P. N.
– sequence: 3
  givenname: Jason R.
  surname: Gee
  fullname: Gee, Jason R.
– sequence: 4
  givenname: H. Barton
  surname: Grossman
  fullname: Grossman, H. Barton
– sequence: 5
  givenname: Arlene O.
  surname: Siefker‐Radtke
  fullname: Siefker‐Radtke, Arlene O.
– sequence: 6
  givenname: Pheroze
  surname: Tamboli
  fullname: Tamboli, Pheroze
– sequence: 7
  givenname: Michelle A.
  surname: Detry
  fullname: Detry, Michelle A.
– sequence: 8
  givenname: Tracy L.
  surname: Robinson
  fullname: Robinson, Tracy L.
– sequence: 9
  givenname: Louis L.
  surname: Pisters
  fullname: Pisters, Louis L.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18848913$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17542024$$D View this record in MEDLINE/PubMed
BookMark eNpt0EtLAzEUBeAgFfvQjXulG10IU29ek8yyFF9QcaPgLqR5QGQ6MybThf_e1FYK4ioEvuTec8Zo0LSNQ-gcwwwDkFvTmDgjRPDyCI0wVKIAzMgAjQBAFpzR9yEap_SRr4JweoKGWHBGgLARungOJrad7kJd6_g1XdXaWhenRjfGxVN07HWd3Nn-nKC3-7vXxWOxfHl4WsyXhSEU-mLFicEYU1mB9s54cAx7i7nIQ6QUtCTWWys8K4232lKpq8pZS7g3lpuS0gm63v3bxfZz41Kv1iEZl1dqXLtJSkDJypKKDC_3cLNaO6u6GNZ5bfUbKIOrPdDJ6NrHnCOkg5OSyQpvJ97sXE6fUnT-QEBtW1XbVtVPqxnDH2xCr_vQNn3Uof7vyTeJeni6
CODEN CANCAR
CitedBy_id crossref_primary_10_1097_COC_0b013e3182a53295
crossref_primary_10_1016_j_eursup_2009_06_009
crossref_primary_10_1111_j_1464_410X_2012_11751_x
crossref_primary_10_1097_MOU_0000000000000356
crossref_primary_10_3389_fsurg_2021_754741
crossref_primary_10_1016_j_juro_2012_10_054
crossref_primary_10_1097_PAT_0b013e3283560172
crossref_primary_10_1038_modpathol_2009_26
crossref_primary_10_1016_j_urology_2010_11_043
crossref_primary_10_3390_biomedicines13010086
crossref_primary_10_1007_s00120_010_2484_4
crossref_primary_10_1111_bju_13689
crossref_primary_10_1097_MOU_0b013e3283495758
crossref_primary_10_3109_00313025_2010_522173
crossref_primary_10_3233_BLC_170156
crossref_primary_10_1016_j_clgc_2020_12_003
crossref_primary_10_1097_MOU_0b013e328356adff
crossref_primary_10_1002_cncr_31952
crossref_primary_10_1016_j_mpdhp_2013_08_005
crossref_primary_10_1038_modpathol_2009_16
crossref_primary_10_1111_his_14161
crossref_primary_10_1007_s11255_022_03358_3
crossref_primary_10_1016_j_eururo_2012_08_009
crossref_primary_10_3390_curroncol30100638
crossref_primary_10_1016_j_urolonc_2014_06_012
crossref_primary_10_1097_PAS_0b013e3181962dcd
crossref_primary_10_2214_AJR_08_1318
crossref_primary_10_1159_000375411
crossref_primary_10_22465_kjuo_2017_15_3_121
crossref_primary_10_4274_uob_galenos_2023_2023_8_1
crossref_primary_10_1111_j_1464_410X_2008_07968_x
crossref_primary_10_1016_j_ypat_2010_11_020
crossref_primary_10_1097_PAS_0000000000002077
crossref_primary_10_1111_j_1442_2042_2010_02672_x
crossref_primary_10_1016_j_juro_2013_07_061
crossref_primary_10_1097_MOU_0b013e328356ade6
crossref_primary_10_1111_j_1464_410X_2009_08694_x
crossref_primary_10_4103_UCCI_UCCI_14_24
crossref_primary_10_1016_j_urolonc_2019_01_026
crossref_primary_10_1016_j_eururo_2016_02_056
crossref_primary_10_2217_fon_2016_0056
crossref_primary_10_32948_auo_2019_07_01
crossref_primary_10_3389_fsurg_2022_1037203
crossref_primary_10_5858_133_1_62
crossref_primary_10_1016_j_urology_2014_06_032
crossref_primary_10_1016_j_urolonc_2014_03_008
crossref_primary_10_1136_jclinpath_2013_201799
crossref_primary_10_5301_RU_2012_9369
crossref_primary_10_1007_s00428_017_2190_3
crossref_primary_10_1007_s11864_024_01187_3
crossref_primary_10_1016_j_juro_2009_02_116
crossref_primary_10_1016_j_urolonc_2012_04_020
crossref_primary_10_1007_s11255_022_03104_9
crossref_primary_10_1038_s41598_020_76904_7
crossref_primary_10_1080_2090598X_2021_1994230
crossref_primary_10_1111_j_1365_2559_2008_03167_x
crossref_primary_10_1007_s00428_016_2001_2
crossref_primary_10_1016_j_eururo_2018_06_024
crossref_primary_10_2169_internalmedicine_7477_21
crossref_primary_10_23736_S2724_6051_23_05091_7
crossref_primary_10_4103_HUAJ_HUAJ_41_21
crossref_primary_10_1111_pin_12314
crossref_primary_10_1111_j_1464_410X_2009_09151_x
crossref_primary_10_1016_j_eururo_2014_08_031
crossref_primary_10_1177_030089161009600231
crossref_primary_10_1007_s00428_016_1986_x
crossref_primary_10_1016_j_juro_2014_09_092
crossref_primary_10_1007_s00345_014_1387_1
crossref_primary_10_1016_j_urolonc_2024_01_002
crossref_primary_10_1016_j_eururo_2016_12_002
crossref_primary_10_1016_j_humpath_2012_04_013
crossref_primary_10_1016_j_eururo_2012_10_008
crossref_primary_10_1097_PAS_0b013e3181a5387b
crossref_primary_10_1155_2011_217153
crossref_primary_10_1097_PAP_0000000000000309
crossref_primary_10_1016_j_urolonc_2018_10_013
crossref_primary_10_1159_000514759
crossref_primary_10_1016_j_eururo_2016_02_028
crossref_primary_10_1016_j_urolonc_2024_09_005
crossref_primary_10_1097_PAP_0b013e3181d97851
crossref_primary_10_1016_j_clgc_2015_09_013
crossref_primary_10_1111_his_13958
crossref_primary_10_4103_1742_6413_107986
crossref_primary_10_1007_s11934_014_0450_1
crossref_primary_10_3892_mco_2024_2778
crossref_primary_10_1097_MOU_0b013e328363e415
crossref_primary_10_1007_s11523_014_0341_x
crossref_primary_10_1016_j_clgc_2023_10_006
crossref_primary_10_1016_j_hoc_2014_10_009
crossref_primary_10_1002_dc_22866
crossref_primary_10_1016_j_euo_2023_07_012
crossref_primary_10_1016_j_humpath_2016_07_014
crossref_primary_10_1016_j_juro_2011_06_012
crossref_primary_10_3233_BLC_190257
crossref_primary_10_1016_j_euo_2019_09_003
crossref_primary_10_3233_BLC_160062
crossref_primary_10_1016_j_euf_2016_06_007
crossref_primary_10_3390_app10207102
crossref_primary_10_1038_nrurol_2011_144
crossref_primary_10_3233_BLC_160066
crossref_primary_10_1111_bju_13780
crossref_primary_10_1016_j_humpath_2009_04_002
crossref_primary_10_1016_j_euf_2020_08_010
crossref_primary_10_1016_j_hoc_2014_10_011
crossref_primary_10_1016_j_clgc_2015_04_008
crossref_primary_10_1080_14737140_2020_1784011
crossref_primary_10_1097_CCO_0b013e32835eb583
crossref_primary_10_1111_ijcp_12075
crossref_primary_10_1200_JCO_2014_57_6967
crossref_primary_10_1016_j_ucl_2013_01_012
crossref_primary_10_1111_cyt_12689
crossref_primary_10_5858_arpa_2017_0539_RA
crossref_primary_10_1007_s13193_022_01692_7
crossref_primary_10_1016_j_anndiagpath_2022_151923
crossref_primary_10_1097_PAS_0b013e3181ec86b3
crossref_primary_10_1016_j_clgc_2019_11_005
crossref_primary_10_1016_j_clgc_2020_06_004
crossref_primary_10_1684_bdc_2010_1097
crossref_primary_10_3109_00313021003767314
crossref_primary_10_1097_PAP_0b013e318199f89e
crossref_primary_10_1016_j_humpath_2009_07_015
crossref_primary_10_1002_dc_21555
crossref_primary_10_1016_j_path_2015_07_004
crossref_primary_10_1111_bju_12877
crossref_primary_10_4103_UCCI_UCCI_16_24
crossref_primary_10_21037_amj_2020_02_02
crossref_primary_10_1016_j_humpath_2009_11_018
crossref_primary_10_1016_j_urolonc_2022_02_004
crossref_primary_10_1016_j_clgc_2023_04_002
crossref_primary_10_1097_MOU_0000000000000089
crossref_primary_10_4132_KoreanJPathol_2013_47_4_365
crossref_primary_10_1016_j_anndiagpath_2019_02_013
crossref_primary_10_1097_MOU_0000000000000086
crossref_primary_10_1016_j_ebiom_2016_08_051
crossref_primary_10_1007_s00428_021_03264_6
crossref_primary_10_1007_s11912_022_01219_x
crossref_primary_10_1016_j_euf_2021_04_005
crossref_primary_10_1016_j_path_2008_07_004
crossref_primary_10_1186_s12894_023_01183_z
crossref_primary_10_1038_nrurol_2017_30
crossref_primary_10_1007_s12094_017_1658_6
crossref_primary_10_1016_j_urolonc_2012_04_009
crossref_primary_10_1016_j_prp_2009_07_016
crossref_primary_10_1016_j_clgc_2020_10_002
crossref_primary_10_1016_j_urolonc_2014_01_020
crossref_primary_10_1186_s13045_022_01291_7
crossref_primary_10_1038_modpathol_2011_69
crossref_primary_10_1093_jjco_hyy066
crossref_primary_10_1016_j_euo_2019_06_012
crossref_primary_10_1016_j_urology_2011_03_021
crossref_primary_10_3390_cancers14215440
crossref_primary_10_1007_s00428_017_2099_x
crossref_primary_10_1038_modpathol_2014_158
crossref_primary_10_1016_j_urolonc_2017_10_013
crossref_primary_10_1097_PAP_0b013e31817d79b9
crossref_primary_10_1186_1471_2490_9_5
crossref_primary_10_5858_arpa_2018_0206_RA
crossref_primary_10_1007_s11912_019_0772_8
crossref_primary_10_1002_dc_24981
crossref_primary_10_1016_j_humpath_2016_10_021
crossref_primary_10_5858_arpa_2011_0463_OA
crossref_primary_10_1016_j_eururo_2018_11_052
crossref_primary_10_1590_S1677_5538_IBJU_2014_02_06
crossref_primary_10_1016_j_eururo_2012_09_063
crossref_primary_10_1186_1471_2407_13_71
crossref_primary_10_1097_PAS_0b013e3181a8ffbe
crossref_primary_10_1016_j_urolonc_2014_10_001
crossref_primary_10_1200_EDBK_438640
crossref_primary_10_1016_j_semradonc_2022_10_008
crossref_primary_10_3233_BLC_170111
crossref_primary_10_1111_j_1464_410X_2007_07271_x
crossref_primary_10_3892_mco_2018_1786
crossref_primary_10_1007_s00345_012_0976_0
crossref_primary_10_1016_j_euf_2021_07_015
crossref_primary_10_1158_1078_0432_CCR_13_1992
crossref_primary_10_32948_auo_2022_12_28
crossref_primary_10_12688_f1000research_14903_1
crossref_primary_10_4081_rt_2011_e22
crossref_primary_10_1111_tid_12072
crossref_primary_10_1016_j_juro_2014_02_2565
crossref_primary_10_1002_cncr_29826
crossref_primary_10_1111_j_1464_410X_2008_07962_x
crossref_primary_10_1097_MOU_0b013e328356aecf
crossref_primary_10_1002_dc_21011
crossref_primary_10_1016_j_humpath_2018_03_015
crossref_primary_10_1007_s11912_011_0161_4
crossref_primary_10_1016_j_urolonc_2008_10_022
crossref_primary_10_1097_MOU_0000000000001023
crossref_primary_10_4236_ss_2012_37068
crossref_primary_10_1016_j_ucl_2013_01_003
crossref_primary_10_1038_nrurol_2017_125
crossref_primary_10_1038_modpathol_2013_201
crossref_primary_10_1016_S0140_6736_16_30512_8
crossref_primary_10_1097_PAS_0000000000001453
crossref_primary_10_1016_j_euf_2019_09_003
crossref_primary_10_1093_ndtplus_sfp025
crossref_primary_10_32948_auo_2021_12_28
crossref_primary_10_1097_PAS_0000000000000241
Cites_doi 10.1016/S0022-5347(05)00423-4
10.1200/JCO.2001.19.20.4005
10.1097/00000478-199412000-00005
10.1016/S0022-5347(05)68807-6
10.1002/cncr.21676
10.1002/cncr.10789
10.3322/canjclin.56.2.106
10.1111/j.1365-2559.2004.01895.x
10.1097/01.ju.0000132413.85866.fc
ContentType Journal Article
Copyright 2007 INIST-CNRS
Copyright (c) 2007 American Cancer Society.
Copyright_xml – notice: 2007 INIST-CNRS
– notice: Copyright (c) 2007 American Cancer Society.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1002/cncr.22756
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0142
EndPage 67
ExternalDocumentID 17542024
18848913
10_1002_cncr_22756
Genre Journal Article
GeographicLocations United States
North America
Texas
America
GeographicLocations_xml – name: Texas
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1L6
1OC
29B
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AAQOH
AARRQ
AAWTL
AAXRX
AAYCA
AAYXX
AAZKR
ABCQN
ABCUV
ABEML
ABHFT
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AEYWJ
AFBPY
AFFNX
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGNAY
AGYGG
AHBTC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C1A
C45
CITATION
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EMOBN
EX3
F00
F01
F04
F5P
FD6
FUBAC
G-S
G.N
GNP
GODZA
GX1
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
H~9
IH2
IX1
J0M
J5H
JPC
KBYEO
KQQ
KZ1
L7B
LATKE
LAW
LC2
LC3
LH4
LITHE
LMP
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
QRW
R.K
ROL
RSU
RX1
RYL
SJN
SUPJJ
TEORI
UDS
UHB
V2E
V8K
V9Y
VH1
W8V
W99
WBKPD
WH7
WHG
WHWMO
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XPP
XV2
Y6R
YQJ
Z0Y
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
24P
AEUQT
AFPWT
CGR
CUY
CVF
DIK
ECM
EIF
NPM
RWI
VXZ
WRC
7X8
ID FETCH-LOGICAL-c230t-b52c1113890afecf0e41fd157420887362dfdd7f46cfdad38a99edd25fcd5c633
ISSN 0008-543X
IngestDate Fri Jul 11 13:29:03 EDT 2025
Wed Feb 19 02:11:26 EST 2025
Mon Jul 21 09:14:25 EDT 2025
Thu Apr 24 22:59:17 EDT 2025
Tue Jul 01 01:22:06 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Human
Urinary system disease
Micropapillary carcinoma
Urinary tract disease
Transitional cell carcinoma
Malignant tumor
Bladder cancer
Chemotherapy
Cystectomy
Cancerology
Treatment
University
Surgery
Bladder disease
micropapillary transitional cell carcinoma
Bibliographic review
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
Copyright (c) 2007 American Cancer Society.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c230t-b52c1113890afecf0e41fd157420887362dfdd7f46cfdad38a99edd25fcd5c633
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17542024
PQID 70646637
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_70646637
pubmed_primary_17542024
pascalfrancis_primary_18848913
crossref_primary_10_1002_cncr_22756
crossref_citationtrail_10_1002_cncr_22756
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-07-01
PublicationDateYYYYMMDD 2007-07-01
PublicationDate_xml – month: 07
  year: 2007
  text: 2007-07-01
  day: 01
PublicationDecade 2000
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Cancer
PublicationTitleAlternate Cancer
PublicationYear 2007
Publisher Wiley-Liss
Publisher_xml – name: Wiley-Liss
References e_1_2_5_9_2
e_1_2_5_8_2
e_1_2_5_7_2
e_1_2_5_10_2
e_1_2_5_6_2
e_1_2_5_5_2
e_1_2_5_4_2
e_1_2_5_3_2
e_1_2_5_2_2
References_xml – ident: e_1_2_5_5_2
  doi: 10.1016/S0022-5347(05)00423-4
– ident: e_1_2_5_6_2
  doi: 10.1200/JCO.2001.19.20.4005
– ident: e_1_2_5_3_2
  doi: 10.1097/00000478-199412000-00005
– ident: e_1_2_5_4_2
  doi: 10.1016/S0022-5347(05)68807-6
– ident: e_1_2_5_10_2
  doi: 10.1002/cncr.21676
– ident: e_1_2_5_8_2
  doi: 10.1002/cncr.10789
– ident: e_1_2_5_2_2
  doi: 10.3322/canjclin.56.2.106
– ident: e_1_2_5_7_2
  doi: 10.1111/j.1365-2559.2004.01895.x
– ident: e_1_2_5_9_2
  doi: 10.1097/01.ju.0000132413.85866.fc
SSID ssj0007253
Score 2.3757727
Snippet Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 62
SubjectTerms Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoma, Papillary - drug therapy
Carcinoma, Papillary - pathology
Carcinoma, Papillary - surgery
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - pathology
Carcinoma, Transitional Cell - surgery
Combined Modality Therapy
Cystectomy - methods
Female
Hospitals, University
Humans
Male
Medical sciences
Middle Aged
Neoadjuvant Therapy - methods
Neoplasm Staging
Nephrology. Urinary tract diseases
Retrospective Studies
Survival Analysis
Texas
Tumors
Tumors of the urinary system
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - surgery
Urinary tract. Prostate gland
Subtitle A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
Title Micropapillary bladder cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/17542024
https://www.proquest.com/docview/70646637
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA66gggi3h0va0BfpExtO-2045vM7jrIdhXpwL6VNBcUls7QdkD9Bf5sz0nSpoMrXl46JSSlnfPl5Evy5RxCXqpqLlmYVNDF-WIaSwVdKqnwLqkYW8y40mk687P5ah2_P09GG-36dElX-fz7pedK_seqUAZ2xVOy_2DZ4aFQAPdgX7iCheH6VzbOUU23ZVvMHNR886oLdCMNCrm4bMwxZnc0xTLMkQyjkF9Z6-W-d-SjsFFzb2-pG-tVX_iRQyRks2IbBgEK1VvJd1pzZMOytmOOa54weHIGnFh7oPYzRk9ya-NfeqXZEhMHeR_drtA7qw5i-EIjiRAM6HbBdoUbJZ2FVL9okQ4CV-eIs2kS61TAzhFbgesYccatGof9i7c30WN5zRs_wjD2bkzr9_HPPpQn69PTsjg-L66SaxHMJfS8-5OLMZZGNlSpfaMhhm302j15j7Xc3LIWOpAymU9-PzXRFKW4TW7ZuQV9a4Byh1yR9V1yPbfqiXvkxz5eqMULNXh5Qxk1aKEbRQEt1KEFSzRaaO7TI5_2aKHG1tSghTq0UEQLhc-jI7TQHi33yfrkuFiupjYTx5TDFLWbVknEYVAEchswJbkKZBwqESYpijOyFEiQUEKkKp5zJZiYZWyxkEJEieIi4fPZ7AE5qDe1fESokKGKRRKygEcxcNmKCQmUtIKJAldxFE7Iq_6fLrkNU4_ZUi5KE2A7KtEqpbbKhLwY6m5NcJZLax3uGcxVzbIYd-kn5HlvwRKcK-6YsVpudm2ZAmEHSp5OyENjWNcWM0cDv338x7ZPyA3XA56Sg67ZyWdAZLvqUAPxJ8Zmo5I
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Micropapillary+bladder+cancer%3A+a+review+of+the+University+of+Texas+M.+D.+Anderson+Cancer+Center+experience+with+100+consecutive+patients&rft.jtitle=Cancer&rft.au=Kamat%2C+Ashish+M&rft.au=Dinney%2C+Colin+P+N&rft.au=Gee%2C+Jason+R&rft.au=Grossman%2C+H+Barton&rft.date=2007-07-01&rft.issn=0008-543X&rft.volume=110&rft.issue=1&rft.spage=62&rft_id=info:doi/10.1002%2Fcncr.22756&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon